The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care
Abstract
Aims To describe initial achievement of glycaemic targets and subsequent hyperglycaemia in patients with Type 2 diabetes managed with oral agent monotherapy in UK primary care from 1998 to 2004. Methods Electronic medical records of patients initiating metformin (n = 3362) or a sulphonylurea agent (n = 3070) in 290 UK primary care practices were retrieved from the General Practice Research Database (GPRD). Patients included had an HbA 1c recorded 0–90 days before and 90–365 days after initiating monotherapy. The probability of achieving glycaemic thresholds in the first year, and for those achieving such targets, the probability of inadequate glycaemic control (HbA 1c > 6.5%, > 7.0%, > 7.5%) over time is described. Results Low baseline HbA 1c and drug initiation within 3 months of diabetes diagnosis were the strongest predictors of initial achievement of glycaemic targets. The proportion of patients with diabetes duration ≥ 4 months who achieved HbA 1c < 7% in the first year ranged from 24% to 88% for highest to lowest baseline HbA 1c category in sulphonylurea initiators and from 19% to 86% in metformin initiators, with slightly higher proportions for newly diagnosed patients. Kaplan–Meier analyses suggested that 55% and 70% of patients who initially achieved glycaemic targets had HbA 1c measurements above these targets at 2 and 3 years. Conclusions Many patients fail to achieve glycaemic goals with initial monotherapy and, of those who achieve current goals, few consistently maintain these targets over 3 years. Research is needed to evaluate whether more aggressive treatment or alternative treatments can improve the long‐term maintenance of glycaemic control in patients with Type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Khaw, K.-T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00006 · Cited by 974
Cited by
Stenlöf, K., Cefalu, W. T., Kim, K. ‐., Alba, M., Usiskin, K., Tong, C., Canovatchel, W., & Meininger, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12054 · Cited by 614
Schernthaner, G., Gross, J. L., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., Kawaguchi, M., Canovatchel, W., & Meininger, G. (2013) · Diabetes Care · doi:10.2337/dc12-2491 · Cited by 480
Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA-REG MET Trial Investigators (2014) · Diabetes Care · doi:10.2337/dc13-2105 · Cited by 400
Raz, I., Chen, Y., Wu, M., Hussain, S., Kaufman, K. D., Amatruda, J. M., Langdon, R. B., Stein, P. P., & Alba, M. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x260925 · Cited by 260
Self-citationSimó, R., Guerci, B., Schernthaner, G., Gallwitz, B., Rosas-Guzmàn, J., Dotta, F., Festa, A., Zhou, M., & Kiljański, J. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0279-z · Cited by 47
Metadata
- Authors
- Cook, M. N., Girman, C. J., Stein, P. P., & Alexander, C. M.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2007-02-28
- Volume
- 24
- Issue
- 4
- Pages
- 350-358
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2027686692
- Cited by
- 197
- References
- 4
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. https://app.cochat.ai/papers/10.1111/j.1464-5491.2007.02078.x
- The paper
- Cook, M. N., Girman, C. J., Stein, P. P., & Alexander, C. M. (2007). Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2007.02078.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.